Metagenomi Inc

NAS:MGX (USA)  
$ 3.58 -0.22 (-5.79%) 11:08 PM EST
At Loss
P/B:
0.49
Market Cap:
$ 134.12M
Enterprise V:
$ -145.22M
Volume:
157.22K
Avg Vol (2M):
101.81K
Trade In:
Volume:
157.22K
At Loss
Avg Vol (2M):
101.81K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for MGX ( Metagenomi Inc ) from 2024 to Jun 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Metagenomi stock (MGX) PE ratio as of Jun 24 2024 is 0. More Details

Metagenomi Inc (MGX) PE Ratio (TTM) Chart

To

Metagenomi Inc (MGX) PE Ratio (TTM) Historical Data

Total 97
  • 1
  • 2
Metagenomi PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-24 At Loss 2024-04-22 At Loss
2024-06-21 At Loss 2024-04-19 At Loss
2024-06-20 At Loss 2024-04-18 At Loss
2024-06-19 At Loss 2024-04-17 At Loss
2024-06-18 At Loss 2024-04-16 At Loss
2024-06-17 At Loss 2024-04-15 At Loss
2024-06-14 At Loss 2024-04-12 At Loss
2024-06-13 At Loss 2024-04-11 At Loss
2024-06-12 At Loss 2024-04-10 At Loss
2024-06-11 At Loss 2024-04-09 At Loss
2024-06-10 At Loss 2024-04-08 At Loss
2024-06-07 At Loss 2024-04-05 At Loss
2024-06-06 At Loss 2024-04-04 At Loss
2024-06-05 At Loss 2024-04-03 At Loss
2024-06-04 At Loss 2024-04-02 At Loss
2024-06-03 At Loss 2024-04-01 At Loss
2024-05-31 At Loss 2024-03-29 At Loss
2024-05-30 At Loss 2024-03-28 At Loss
2024-05-29 At Loss 2024-03-27 At Loss
2024-05-28 At Loss 2024-03-26 At Loss
2024-05-27 At Loss 2024-03-25 At Loss
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss

Metagenomi Inc (MGX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Metagenomi Inc
NAICS : 541713 SIC : 2834
ISIN : US59102M1045
Compare
Compare
Traded in other countries / regions
MGX.USA
IPO Date
2024-02-09
Description
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).